Form 4: ADPT CFO Sells Shares for Tax Obligations

Adaptive Biotechnologies' CFO, Kyle Piskel, sold 238 shares of common stock in a non-discretionary transaction to cover tax withholding related to RSU vesting.

Summary

• Kyle Piskel, Chief Financial Officer of Adaptive Biotechnologies Corp (ADPT), reported a sale of company common stock.
• The transaction, dated November 17, 2025, involved the disposition of 238 shares at a price of $14.05 per share.
• This sale was not a discretionary trade by Mr. Piskel but was mandated by the company's equity incentive plans to satisfy tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).
• Following this transaction, Mr. Piskel directly beneficially owns 269,343 shares of Adaptive Biotechnologies common stock.

Sentiment

Score: 5

Explanation: Neutral. This is a routine, non-discretionary transaction for tax purposes and does not reflect a change in management's view of the company's prospects.

Future Outlook

No future outlook or guidance is provided in this Form 4 filing, as it pertains solely to an insider transaction.

Management Comments

• "This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs."
• "This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary trade by the Reporting Person."

Industry Context

This filing details a routine insider transaction common across all industries for executives receiving equity compensation. It does not provide specific insights into broader industry trends or competitive landscape for Adaptive Biotechnologies.

Comparison to Industry Standards

• This 'sell to cover' transaction is a common and standard practice for executives across various industries, including biotechnology, to manage tax liabilities arising from the vesting of equity awards like Restricted Stock Units (RSUs). It aligns with typical corporate equity compensation plan administration.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary tax-related sale, not indicative of a change in confidence by the CFO.

Key Dates

Recommendation

This Form 4 reports a routine 'sell to cover' transaction by the CFO to satisfy tax obligations upon RSU vesting. It is not a discretionary sale and therefore does not provide new information that would warrant a change in investment recommendation. Investors should consider broader company fundamentals and market conditions.

Keywords

Adaptive Biotechnologies, ADPT, Form 4, Insider Trading, Stock Sale, CFO, Kyle Piskel, RSU Vesting, Tax Withholding, Equity Incentive Plan